**Impact Statement Template**

**VS 1**

**Up to 30 % of the 20 000 patients that will receive a new kidney transplant will reject it. it’s a challenge to sufficiently prevent rejection. Today, their best option is multiple immunosuppressant drugs for life, which, because of the need to balance the side-effects with the drug’s efficacy means it does not always work and yields in rejection. Thus, there is a need to/for improved patient-specific treatment, which, if solved, would have 50% decreased rejections and improved quality of life. Solving this need can be achieved by dampening the immune system with ultrasound while increasing the frequency of monitoring, which will be proven by a 50% reduction in rejection rates.**

Worse case scenario: improve the treatment with all drugs

Best case: improve the treatment AND eliminate some of the drugs.

For Up to 30 % of the 20 000 patients that will receive a new kidney transplant will reject it.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 [who? Patient, provider, other, stakeholder]

it’s a challenge to sufficiently prevent rejection.\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

 [accomplish a key activity; achieve a primary goal]

Today, their best option is a cocktail of immunosuppressant drugs\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ ,

 [current approach or status; emerging solutions]

which, because of the need to balance the side-effects with the drug’s efficacy means it does not always work and \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 [primary functional problem relating to activity]

yields to kidney rejection\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

 [bad/worst case outcomes or limitations]

Thus, there is a need to/for improved patient-specific treatment\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 [describe the unmet need in specific terms]

which, if solved, would have 50% decreased rejections and improved quality of life \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 [describe the specific impact in detailed, ideally quantifiable, terms]

Solving this need can be achieved by dampening the immune system with ultrasound while increasing the frequency of monitoring\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 [specific solution approach that will achieve the quantifiable impact]

and will be demonstrated/proven by reduced rejection\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

[what specifically will be measured to demonstrate the intended impact]

**VS 0**

For patients who received a new kidney, it’s a challenge to detect and prevent rejection. Today, their best option is immunosuppressant drugs, which have dangerous side effects and yields a poor quality of life. Additionally, the current standard of care only screens these patients 4 times a year, yielding late detection. Thus, INIA has a tool to detect rejection at the earliest biological sign as well as a safer treatment option, which if solved, could save organs. Solving this need can be achieved via ultrasound stimulation of the spleen to dampen the immune system while regularly monitoring rejection markers, which will be proven by the reduce rejection rates.